Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

27th May 2015 by Louise Hudman

Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

This new guideline from Nice states that rivaroxaban can now be used after ACS with elevated cardiac enzymes. It should be used either with aspirin, or with aspirin and clopidogrel together.

  • It decreases the combined end points of MI, CVA or deaths from cardiovascular events by 20%.
  • There is a 3 x increased risk of major bleeding, so bleeding risk must be assessed.
  • Use beyond 12m hasn’t been studied, so use beyond that point is for clinical judgement.

It is generally started about a week after the event, so it is likely that we will be starting it, though hopefully it will be advised in the discharge summary.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"LocumDeck does everything you want it to do in an instant and with audit trails.

I absolutely love the facility for receiving Locum's invoices and the facility for signing the Pension Forms electronically and they are then instantly sent with an audit trail! It is fabulous!

You are notified the moment a Locum GP adds availability which is just fantastic, I spend a lot of time just chasing agencies to see if they have availability, so to be notified the moment availability is advertised is a new concept and very welcome! I have no hesitation in recommending LocumDeck - it has already eased my workload!"

Sue, Practice Manager in Portsmouth

See the full list of features within our NASGP membership plans

Membership